JP6951336B2 - 小分子カクテルによるヒトグリア細胞からニューロンへの化学的リプログラミング - Google Patents
小分子カクテルによるヒトグリア細胞からニューロンへの化学的リプログラミング Download PDFInfo
- Publication number
- JP6951336B2 JP6951336B2 JP2018527791A JP2018527791A JP6951336B2 JP 6951336 B2 JP6951336 B2 JP 6951336B2 JP 2018527791 A JP2018527791 A JP 2018527791A JP 2018527791 A JP2018527791 A JP 2018527791A JP 6951336 B2 JP6951336 B2 JP 6951336B2
- Authority
- JP
- Japan
- Prior art keywords
- cri
- flu
- compound
- pfd
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
- C12N2501/734—Proteases (EC 3.4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本出願は、2015年12月4日出願の米国特許仮出願第62/263,353号に対して優先権を主張するものであり、その開示は、参照によって本明細書に援用されている。
本実施例は、本明細書に記載のFDA認可済み薬物群が、ヒトグリア細胞をニューロンへin vitroで変換できることを実証する。
本実施例は、成体マウス及びアルツハイマー病のトランスジェニックマウスモデルに、化合物の群を頭蓋内投与を用いることによって、本開示の態様である、in vivoでの実施態様の非限定的な例を提示する。特に、図3Aは、新生ニューロンマーカーダブルコルチン(DCX、緑色(green))及び細胞増殖マーカーKi67(赤色(red))の免疫染色によって明らかなように、クリゾチニブ50μM、フルルビプロフェン0.2mM、ピルフェニドン2μM、ビタミンC10mg/ml、及びLiCl0.4Mを含む小分子カクテル2μlを3ヶ月のWTマウスの海馬に頭蓋内注射することによって、成体神経発生が促進されたことを示す。図3B。DCX陽性の新たなニューロン及びKi67陽性増殖細胞の数の増加によって支持されるように、1歳の成体WTマウスの海馬に小分子カクテルを頭蓋内注射することによって、歯状回(DG)の成体神経発生が有意に促進された。図3C。5ヶ月の、アルツハイマー病のトランスジェニックマウスモデルの海馬に小分子カクテルを頭蓋内注射することによって、DGのDCX陽性の新たなニューロンの数が有意に増加した。図3D。GFAP::GFPマウスにおいて、星状細胞はGFPによって標識される。系列追跡分析によれば、DCX+の新たなニューロンが、小分子カクテルによってGFP標識星状細胞から誘発された。図3E、図3F、及び図3Gは、DCX+の新たなニューロンの数が、3ヶ月のWTマウス(図3E)、1歳の成体WTマウス(図3F)、及び5ヶ月のアルツハイマー病のトランスジェニックマウスモデル(図3G)の海馬に小分子カクテルを頭蓋内注射することによって増加したことを示す定量解析を表す。スチューデントt検定、*P<0.05、**P<0.01、1群あたりn=3マウス。
本実施例は、本明細書に記載のFDA認可済み薬物群の腹腔内注射することによって、マウス脳の成体神経発生を増やすこともできることの実証を提示する。特に、図4A及び図4Bは、ビヒクル対照(図4A、20%Captisol)、又はクリゾチニブ50μM、フルルビプロフェン0.2mM、ピルフェニドン2μM、ビタミンC10mg/ml、及びLiCl0.4Mを含む化合物の群カクテル(図4B)を腹腔内注射した後の(投与量0.1ml/10g重量、1ヶ月間毎日注射された3ヶ月のWTマウス)、海馬の歯状回の成体神経発生を示す代表的な画像を提示する。化学的処置の7日後、マウスを屠殺して、新生ニューロンマーカーDCXの免疫染色を用いて調べた(図4C)。定量解析によれば、FDA認可済み薬物カクテルで処理されたDCX+ニューロンの数が増加したことが明らかになった。スチューデントt検定、*P<0.05、n=2ペア。
Claims (21)
- グリア細胞からニューロンを生成するための医薬の製造における組成物の使用であって、
前記組成物は、
クリゾチニブ(Cri)、フルルビプロフェン(Flu)、塩化リチウム(Li)からなる主化合物と、
ビタミンC(VC)、セリチニブ(Cer)、及びピルフェニドン(PFD)から選択される少なくとも1種の追加の化合物と
を含む化合物の群を含む、医薬組成物の製造における使用。 - 前記主化合物と前記追加の化合物を含む化合物の群は、前記主化合物と、前記追加の化合物が2種とを含む、請求項1に記載の医薬組成物の製造における使用。
- 前記主化合物と前記追加の化合物を含む化合物の群は、前記主化合物と、前記追加の化合物が1種のみとを含む、請求項1に記載の医薬組成物の製造における使用。
- 前記主化合物と前記追加の化合物を含む化合物の群は、前記主化合物と、前記追加の化合物が2種のみとを含む、請求項1に記載の医薬組成物の製造における使用。
- 前記主化合物と前記追加の化合物を含む化合物の群は、
i)Cer/Cri/Li/Flu/VC、
ii)PFD/Cri/Li/Flu/VC、
iii)Cer/Cri/Li/Flu、
又はiv)PFD/Cri/Li/Fluを含む、請求項1に記載の医薬組成物の製造における使用。 - 前記主化合物と前記追加の化合物を含む化合物の群は、
i)Cer/Cri/Li/Flu/VC、
ii)Cri/Flu/PFD/VC/Li、
iii)Cer/Cri/Li/Flu、
又はiv)PFD/Cri/Li/Fluのみからなる、請求項1に記載の医薬組成物の製造における使用。 - 前記グリア細胞が、哺乳動物の脳、又は脊髄、又は末梢神経系に存在する、請求項1から6のいずれか一項に記載の医薬組成物の製造における使用。
- 前記主化合物と前記追加の化合物を含む化合物の群は、
Cri/Flu/PFD/VC/Liを含む、請求項7に記載の医薬組成物の製造における使用。 - 前記主化合物と前記追加の化合物を含む化合物の群は、
前記Cri/Flu/PFD/VC/Liのみからなる、請求項8に記載の医薬組成物の製造における使用。 - 前記医薬組成物が、ニューロンの欠損、グリア性瘢痕、神経傷害、加齢、神経変性、小頭症、重篤な発作、又はそれらの任意の組み合わせから選択される状態のために、前記ニューロンを必要とする個体に投与されるものである、請求項7に記載の医薬組成物の製造における使用。
- 前記医薬組成物が、虚血性脳損傷のために前記ニューロンを必要とする個体に投与されるものである、請求項7に記載の医薬組成物の製造における使用。
- 前記医薬組成物が、アルツハイマー病と診断されたか、又はアルツハイマー病を患っていると疑われる個体に投与されるものである、請求項7に記載の医薬組成物の製造における使用。
- クリゾチニブ(Cri)、フルルビプロフェン(Flu)、塩化リチウム(Li)からなる主化合物と、
ビタミンC(VC)、セリチニブ(Cer)、及びピルフェニドン(PFD)から選択される少なくとも1種の追加の化合物と
を含む化合物の群を含む、グリア細胞のニューロンへの変換するための医薬組成物。 - クリゾチニブ(Cri)、フルルビプロフェン(Flu)、塩化リチウム(Li)からなる主化合物と、
ビタミンC(VC)、セリチニブ(Cer)、及びピルフェニドン(PFD)から選択される少なくとも1種の追加の化合物と
を含む化合物の群を含む、アルツハイマー病等の脳障害の治療するための医薬組成物。 - 前記主化合物と前記追加の化合物を含む化合物の群は、
i)Cer/Cri/Li/Flu/VC、
ii)Cri/Flu/PFD/VC/Li、
iii)Cer/Cri/Li/Flu、
又はiv)PFD/Cri/Li/Fluを含む、請求項13又は14に記載の医薬組成物。 - 前記主化合物と前記追加の化合物を含む化合物の群は、
Cri/Flu/PFD/VC/Liを含む、請求項13又は14に記載の医薬組成物。 - 前記主化合物と前記追加の化合物を含む化合物の群は、
前記Cri/Flu/PFD/VC/Liのみからなる、請求項15に記載の医薬組成物。 - クリゾチニブ(Cri)、フルルビプロフェン(Flu)、塩化リチウム(Li)からなる主化合物と、
ビタミンC(VC)、セリチニブ(Cer)およびピルフェニドン(PFD)から選択される少なくとも1種の追加の化合物と
を含む化合物の群を含む、グリア細胞のニューロンへの変換するための医薬組成物を含む製品であって、前記化合物の群が、機能性ニューロンの必要性に関連する状態を処置するのに使用されるという指示を示す印刷物をさらに含む、グリア細胞のニューロンへの変換するための製品。 - クリゾチニブ(Cri)、フルルビプロフェン(Flu)、塩化リチウム(Li)からなる主化合物と、
ビタミンC(VC)、セリチニブ(Cer)およびピルフェニドン(PFD)から選択される少なくとも1種の追加の化合物と
を含む化合物の群を含む、アルツハイマー病等の脳障害の治療するための医薬組成物を含む製品であって、前記化合物の群が、機能性ニューロンの必要性に関連する状態を処置するのに使用されるという指示を示す印刷物をさらに含む、アルツハイマー病等の脳障害の治療するための製品。 - 前記主化合物と前記追加の化合物を含む化合物の群は、
i)Cer/Cri/Li/Flu/VC、
ii)Cri/Flu/PFD/VC/Li、
iii)Cer/Cri/Li/Flu、
又はiv)PFD/Cri/Li/Fluを含む、請求項18又は19に記載の製品。 - 前記主化合物と前記追加の化合物を含む化合物の群は、
Cri/Flu/PFD/VC/Liを含む、請求項18又は19に記載の製品。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562263353P | 2015-12-04 | 2015-12-04 | |
US62/263,353 | 2015-12-04 | ||
PCT/US2016/064553 WO2017096123A1 (en) | 2015-12-04 | 2016-12-02 | Chemical reprogramming of human glial cells into neurons with small molecule cocktail |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018535988A JP2018535988A (ja) | 2018-12-06 |
JP6951336B2 true JP6951336B2 (ja) | 2021-10-20 |
Family
ID=58797771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018527791A Active JP6951336B2 (ja) | 2015-12-04 | 2016-12-02 | 小分子カクテルによるヒトグリア細胞からニューロンへの化学的リプログラミング |
Country Status (10)
Country | Link |
---|---|
US (2) | US9885015B2 (ja) |
EP (2) | EP3383495B1 (ja) |
JP (1) | JP6951336B2 (ja) |
KR (2) | KR102102837B1 (ja) |
CN (2) | CN108430582B (ja) |
AU (1) | AU2016364845B2 (ja) |
CA (1) | CA3007116A1 (ja) |
HK (1) | HK1256307A1 (ja) |
SG (1) | SG11201804440XA (ja) |
WO (1) | WO2017096123A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201800001168A1 (it) * | 2018-01-17 | 2019-07-17 | Fond Per Listituto Oncologico Di Ricerca Ior | Nuovi farmaci senolitici inibitori alk |
EP3955742A4 (en) * | 2019-04-18 | 2023-05-24 | Brown University | NEUROGENESIS |
JP2023502785A (ja) * | 2019-11-25 | 2023-01-25 | ザ・ペン・ステイト・リサーチ・ファウンデイション | ヒトグリア細胞をニューロンに変換するための組成物および方法 |
WO2021195706A1 (en) * | 2020-03-31 | 2021-10-07 | Children's Medical Research Institute | New dynamin inhibitors and uses |
WO2022095057A1 (zh) * | 2020-11-09 | 2022-05-12 | 深圳先进技术研究院 | 一种医药组合物及其医药用途 |
CN113244236B (zh) * | 2021-06-01 | 2023-02-03 | 上海市第一人民医院 | 色瑞替尼在制备治疗甲状腺相关眼病的药物中的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0202249A3 (en) * | 1999-07-09 | 2003-01-28 | Ortho Mcneil Pharm Inc | Neurotrophic pyrrolidines and piperidines, compositions containing them and use of the compounds |
GB0316882D0 (en) * | 2003-07-18 | 2003-08-20 | Consejo Superior Investigacion | Reversible immortalization of OEG from human olfactory bulbs as a tool to promote spinal cord regeneration |
WO2008125902A2 (en) * | 2006-03-09 | 2008-10-23 | University Of Rochester | Peripheral and neural inflammatory crosstalk |
CN101732255A (zh) | 2010-01-07 | 2010-06-16 | 同济大学 | 一种氟比洛芬脂质体及其制备方法 |
PT2577318T (pt) * | 2010-05-25 | 2019-10-14 | Memorial Sloan Kettering Cancer Center | Método de diferenciação de nocicetor de células estaminais embrionárias humanas e utilizações do mesmo |
CN114601937A (zh) * | 2012-07-19 | 2022-06-10 | 宾夕法尼亚州研究基金会 | 再生用于在神经系统中治疗疾病和损伤的功能性神经元 |
EP3881857A1 (en) * | 2016-02-18 | 2021-09-22 | The Penn State Research Foundation | Generating gabaergic neurons in brains |
KR20220030271A (ko) * | 2019-06-28 | 2022-03-10 | 더 펜 스테이트 리서어치 파운데이션 | 헌팅턴병을 치료하기 위한 방법 및 재료 |
-
2016
- 2016-12-02 WO PCT/US2016/064553 patent/WO2017096123A1/en active Application Filing
- 2016-12-02 US US15/367,382 patent/US9885015B2/en active Active
- 2016-12-02 CN CN201680077502.1A patent/CN108430582B/zh active Active
- 2016-12-02 CN CN202010064422.0A patent/CN111184739B/zh active Active
- 2016-12-02 EP EP16871554.8A patent/EP3383495B1/en active Active
- 2016-12-02 AU AU2016364845A patent/AU2016364845B2/en active Active
- 2016-12-02 SG SG11201804440XA patent/SG11201804440XA/en unknown
- 2016-12-02 CA CA3007116A patent/CA3007116A1/en active Pending
- 2016-12-02 JP JP2018527791A patent/JP6951336B2/ja active Active
- 2016-12-02 KR KR1020187019038A patent/KR102102837B1/ko active IP Right Grant
- 2016-12-02 KR KR1020207010846A patent/KR102444438B1/ko active IP Right Grant
- 2016-12-02 EP EP20207658.4A patent/EP3795147B1/en active Active
-
2017
- 2017-12-01 US US15/828,652 patent/US10253293B2/en active Active
-
2018
- 2018-11-30 HK HK18115373.5A patent/HK1256307A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201804440XA (en) | 2018-06-28 |
AU2016364845B2 (en) | 2022-07-28 |
US9885015B2 (en) | 2018-02-06 |
JP2018535988A (ja) | 2018-12-06 |
EP3383495A4 (en) | 2019-09-04 |
US10253293B2 (en) | 2019-04-09 |
HK1256307A1 (zh) | 2019-09-20 |
KR102102837B1 (ko) | 2020-04-22 |
KR102444438B1 (ko) | 2022-09-19 |
EP3383495A1 (en) | 2018-10-10 |
EP3795147A1 (en) | 2021-03-24 |
AU2016364845A1 (en) | 2018-06-21 |
EP3795147B1 (en) | 2023-08-30 |
KR20200043503A (ko) | 2020-04-27 |
CA3007116A1 (en) | 2017-06-08 |
CN111184739A (zh) | 2020-05-22 |
CN108430582B (zh) | 2020-02-21 |
US20180148688A1 (en) | 2018-05-31 |
EP3383495B1 (en) | 2021-01-20 |
WO2017096123A1 (en) | 2017-06-08 |
KR20180081824A (ko) | 2018-07-17 |
US20170159013A1 (en) | 2017-06-08 |
CN111184739B (zh) | 2022-06-24 |
CN108430582A (zh) | 2018-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6951336B2 (ja) | 小分子カクテルによるヒトグリア細胞からニューロンへの化学的リプログラミング | |
US20220071929A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
Van Bulck et al. | Novel approaches for the treatment of Alzheimer’s and Parkinson’s disease | |
Deyama et al. | Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine | |
Johnson et al. | Pharmacotherapy for amyotrophic lateral sclerosis: a review of approved and upcoming agents | |
ES2938546T3 (es) | Método de tratamiento de la esclerosis lateral amiotrófica con pridopidina | |
Lamy et al. | Recent advances in the pharmacological management of behavioral disturbances associated with autism spectrum disorder in children and adolescents | |
Md Ashraf et al. | An overview on global trends in nanotechnological approaches for Alzheimer therapy | |
Fischer et al. | BDNF provides many routes toward STN DBS‐mediated disease modification | |
JP2019529411A (ja) | 不安症およびうつ病の治療のためのプリドピジンの使用 | |
JP2020514313A (ja) | 脆弱x症候群の治療のためのプリドピジンの使用 | |
Peña-Díaz et al. | Development of small molecules targeting α-synuclein aggregation: a promising strategy to treat Parkinson’s disease | |
Gutierrez et al. | Prevention of cognitive decline | |
Orsolini et al. | Long-acting paliperidone in Ekbom’s syndrome in Lewy body dementia: A case report | |
CN112566633A (zh) | 增强中枢神经系统中葡萄糖水平的方法 | |
Li | Intra-maxillary Molecular Releasing and its Application in the Assistance of Neurodegenerative Disease Therapeutics | |
Jain | Check for Pathophysiology and Management Approaches in Alzheimer's Disease Shreshta Jain, Divya Goel, Sheikh Sana Nazir, Vaishali Yadav, and Divya Vohora | |
Altunkaynak et al. | Effects of Methylphenidate and Atomoxetine on Development of the Brain | |
Samim et al. | Pathophysiology and Management Approaches for Parkinson’s Disease | |
Di Franco | Development and characterization of a new therapeutic approach of the Down Syndrome targeting the type-1 cannabinoid receptor | |
Elgar | Nutritional medicine reviews N-acetylcysteine: A review of clinical use and efficacy | |
Er | GDNF/RET signaling and its downstream pathways eliminate alpha-synuclein pathology in dopamine neurons | |
Yang et al. | Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease | |
CN115135312A (zh) | 用于将人类神经胶质细胞转化为神经元的组合物和方法 | |
Mukaetova-Ladinska et al. | Molecular Basis of Cholinergic Changes in Autism Spectrum Disorders and Relevance for Treatment Interventions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190723 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200918 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210202 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210511 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210804 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210831 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210924 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6951336 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |